# Jong-Mu Sun

Source: https://onco.cc/people/jong-mu-sun/  
OnCo record `jong-mu-sun` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Korean oncologist who was lead author of KEYNOTE-590, the trial that added pembrolizumab to first-line chemotherapy for advanced oesophageal cancer.

## Summary

Jong-Mu Sun is a medical oncologist at Samsung Medical Center in Seoul. He was first author of the 2021 Lancet report of KEYNOTE-590, which showed that pembrolizumab plus cisplatin and fluorouracil improved overall survival compared with chemotherapy alone in untreated advanced oesophageal cancer, the basis for pembrolizumab's approval in this setting. He also runs thoracic oncology trials.

## Fields

- Kind: Person
- Last checked: 2026-09-18
- Tags: oesophageal; immunotherapy; trialist
- Role: Medical oncologist, Samsung Medical Center, Seoul
- Specialisms: Oesophageal cancer; Lung cancer; Immunotherapy

## Connected records

- cancers: [Oesophageal and junctional adenocarcinoma](https://onco.cc/cancers/oesophageal-adenocarcinoma/), [Oesophageal cancer](https://onco.cc/cancers/esophageal/), [Oesophageal squamous cell carcinoma](https://onco.cc/cancers/oesophageal-squamous-cell-carcinoma/)
- institutions: [Samsung Medical Center](https://onco.cc/institutions/samsung-medical-center/)
- key papers: [KEYNOTE-590: pembrolizumab plus chemotherapy for first-line treatment of advanced oesophageal cancer](https://onco.cc/key-papers/paper-keynote-590-lancet-2021/)

---
JSON: https://onco.cc/api/v1/entities/jong-mu-sun.json